Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960230 · ClinicalTrials.gov registry record · Phase 1
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
A Phase 1 study, sponsored by Sabine Mueller, MD, PhD.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02960230 is a Phase 1 study that has completed, run by Sabine Mueller, MD, PhD. The registered enrollment target is 50 participants.
The verdict
NCT02960230, a Phase 1 study, has completed, sponsored by Sabine Mueller, MD, PhD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is 3-arm, multicenter study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC). This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the Histone 3 lysine27-to-methionine (H3.3K27M) epitope given in combination with poly-ICLC and the H3.3K27M epitope given in combination with poly-ICLC and the PD-1 inhibitor, nivolumab, in HLA-A2 (02:01)+ children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or other midline gliomas that are positive for H3.3K27M.
Interventions
- DRUG Nivolumab
- BIOLOGICAL K27M peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960230
The ClinicalTrials.gov registry entry for NCT02960230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02960230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02960230 about?
NCT02960230 is a clinical study titled "H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas". This is 3-arm, multicenter study that will be conducted through the Pacific Pediatric Neuro-oncology Consortium (PNOC). This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the Histone 3 lysine27-to-methionine (H3.3K27M) epitope given in combination with ...
What is the current status of trial NCT02960230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2016-11-18. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT02960230?
The interventions under investigation include: Nivolumab (DRUG), K27M peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT02960230?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.